Cas no 135062-02-1 (Repaglinide)

Repaglinide is a short-acting meglitinide-class antidiabetic agent used to manage type 2 diabetes mellitus by stimulating insulin secretion from pancreatic β-cells. Its rapid absorption and short half-life (~1 hour) allow for precise postprandial glucose control, reducing the risk of prolonged hypoglycemia. Repaglinide acts by binding to the SUR1 subunit of pancreatic KATP channels, promoting insulin release in a glucose-dependent manner, which enhances safety in fasting states. It is metabolized primarily by CYP3A4 and CYP2C8, necessitating caution with concomitant enzyme inhibitors or inducers. The drug is particularly advantageous for patients with irregular meal schedules due to its flexible dosing regimen (taken shortly before meals). Clinical studies demonstrate efficacy in lowering HbA1c levels while minimizing weight gain.

Repaglinide structure

Product Name:Repaglinide

CAS No:135062-02-1

MF:C₂₇H₃₆N₂O₄

MW:452.5857

MDL:MFCD00906179

CID:64339

PubChem ID:24724596

Update Time:2025-11-02

Repaglinide Chemical and Physical Properties

Names and Identifiers

- (S)-2-Ethoxy-4-(2-((3-methyl-1-(2-(piperidin-1-yl)phenyl)butyl)amino)-2-oxoethyl)benzoic acid
- 4-Ethoxycarbonyl-3-ethoxy phenyl acetic acid
- AG-EE 623ZW
- Repaglinide
- 2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid
- 2-Ethoxy-4-[2-[[(1S)-3-Methyl-1-[2-(1-Piperidinyl)Phenyl]Butyl]Amino]-2-Oxoethyl]Benzoic Acid
- Prandin,GlucoNorm,NovoNorm
- (S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid
- Novonorm
- Prandin
- GlucoNorm
- Repaglinidum
- Repaglinida
- Repaglinidum [INN-Latin]
- Repaglinida [INN-Spanish]
- C27H36N2O4
- 668Z8C33LU
- 2-Ethoxy-4-[2-[[(1S)-3-Methyl-1-[2-(1-Piperidinyl)Phenyl]Buty
- AKOS005561792
- BRD-K82846253-001-03-0
- (S)-2-ETHOXY-4-(2-(METHYL-1-(2-(1-PIPERIDINYL)PHENYL)BUTYLAMINO)-2-OXOETHYL)-BENZOIC ACID
- REPAGLINIDE [VANDF]
- HMS3414D09
- Q2195995
- 2-ethoxy-4-[2-({(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl}amino)-2-oxoethyl]benzoic acid
- SW197344-4
- Repaglinide for system suitability, European Pharmacopoeia (EP) Reference Standard
- BJX
- Q-201663
- AM20090697
- 2-ethoxy-4-({[(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]carbamoyl}methyl)benzoic acid
- HMS2094C07
- NN-623
- F15001
- BIDD:GT0338
- Prestwick3_001046
- SMR000466305
- Reglin
- (S)-2-Ethoxy-4-(2-((3-methyl-1-(2-(piperidin-1-yl)phenyl)butyl)amino)-2-oxoethyl)benzoicacid
- REPAGLINIDE (MART.)
- Repaglinida (INN-Spanish)
- (+)-2-Ethoxy-alpha-(((S)-alpha-isobutyl-o-piperidinobenzyl)carbamoyl)-p-toluic acid
- Benzoic Acid, 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-,(S)-
- Surepost
- Benzoic acid, 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-, (S)-
- A10BX02
- AG-EE 623 ZW
- SMP-508
- AG-EE-623-ZW
- MLS000759407
- repa-glinide
- Repaglinide [USAN:USP:INN:BAN]
- REPAGLINIDE [USP MONOGRAPH]
- NCGC00016978-05
- REPAGLINIDE (EP MONOGRAPH)
- (S)-2-Ethoxy-4-[N-(1-(2-piperidino-phenyl)-3-methyl-1-butyl)-aminocarbonylmethyl]-benzoic acid
- s1426
- BDBM50153520
- Z1501485370
- AB00514019_10
- (S)-2-Ethoxy-4-(2-(3-methyl-1-(2-piperidinophenyl)butylamino)-2-oxoethyl)benzoic acid
- 111GE012
- Actulin
- CCG-101013
- FAEKWTJYAYMJKF-QHCPKHFHSA-N
- AB00514019_11
- SBI-0206942.P001
- SPBio_002906
- D00594
- Repaglinide [USAN]
- MLS001424111
- AB00514019-09
- Repaglinide, European Pharmacopoeia (EP) Reference Standard
- Tox21_110721
- BPBio1_001070
- GTPL6841
- NSC 759893
- Pharmakon1600-01506035
- BCP04250
- AG-EE 388 ZW
- Repaglinide for system suitability
- Repaglinide, United States Pharmacopeia (USP) Reference Standard
- (S)-2-Ethoxy-4-[2-[[3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]amino]-2-oxoethyl]benzoic acid
- NCGC00016978-02
- AG-EE-623 ZW
- Repaglinide (JAN/USP/INN)
- HMS3678D09
- (-)-Repaglinide
- SCHEMBL16137
- A806877
- AC-726
- (S)-2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)-phenyl)butyl)amino)-2-oxoethyl)-benzoic acid
- MFCD00906179
- BSPBio_000972
- HB1106
- (S)-2-ethoxy-4-(2-(3-methyl-1-(2-(piperidin-1-yl)phenyl)butylamino)-2-oxoethyl)benzoic acid
- AG-EE-388
- REPAGLINIDE [MI]
- REPAGLINIDE [MART.]
- 2-Ethoxy-4-[2-[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benz oic acid
- HMS2098A14
- REPAGLINIDE [JAN]
- Repaglinide,(S)
- BR164332
- AGEE-623ZW
- HMS2231M21
- NCGC00016978-01
- (+)-2-ETHOXY-.ALPHA.-(((S)-.ALPHA.-ISOBUTYL-O-PIPERIDINOBENZYL)CARBAMOYL)-P-TOLUIC ACID
- REPAGLINIDE [EMA EPAR]
- REPAGLINIDE [INN]
- HMS3715A14
- HMS2051N08
- Repaglinide (USAN:USP:INN:BAN)
- REPAGLINIDE (USP MONOGRAPH)
- C07670
- AB00514019
- REPAGLINIDE (USP-RS)
- BS-1010
- Repaglinide, >=98% (HPLC), solid
- 135062-02-1
- CHEMBL1272
- CHEBI:8805
- SR-01000759404-4
- HY-15209
- (2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-5-guanidino-pentanoyl]amino]-4-carboxy-butanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]acetyl]amino]-4-methyl-pentanoyl]amino]-3-methyl-pe;(S)-2-Ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidyl)phenyl]butyl]amino]-2-oxoethyl]benzoic Acid
- Prestwick1_001046
- 2-ethoxy-4-(2-{[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino}-2-oxoethyl)benzoic acid
- (s)-(+)-2-ethoxy-4-(2-oxo-2-[(alpha-isobutyl-2-piperidinobenzyl)amino]ethyl)-benzoic acid
- Prestwick2_001046
- HMS1571A14
- REPAGLINIDE [ORANGE BOOK]
- NSC-759893
- (S)-2-Ethoxy-4-[2-[[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benzoic Acid
- CAS-135062-02-1
- Prestwick0_001046
- UNII-668Z8C33LU
- DB00912
- DTXCID603552
- Prandin (TN)
- MLS006011560
- Repaglinidum (INN-Latin)
- Surepost (TN)
- CS-0979
- DTXSID3023552
- REPAGLINIDE [USP-RS]
- NSC759893
- (+)-repaglinide
- AG-EE-623ZW
- MLS001076684
- REPAGLINIDE [EP MONOGRAPH]
- R0179
- REPAGLINIDE [WHO-DD]
- (S)-2-Ethoxy-4-(2-((methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-benzoic acid
- Benzoic acid, 2-ethoxy-4-[2-[[(1S)-3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]-
- NCGC00016978-04
- SR-01000759404
- Repaglinide- Bio-X
- NC00263
- 2-Ethoxy-4-{[(S)-3-methyl-1-(2-piperidin-1-yl-phenyl)-butylcarbamoyl]-methyl}-benzoic acid
- BRD-K82846253-001-14-7
- BRD-K82846253-001-15-4
- BRD-K82846253-001-16-2
- NCGC00016978-15
- STK629501
- MDL： MFCD00906179
- Inchi： 1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1
- InChI Key： FAEKWTJYAYMJKF-QHCPKHFHSA-N
- SMILES： O=C(C([H])([H])C1C([H])=C([H])C(C(=O)O[H])=C(C=1[H])OC([H])([H])C([H])([H])[H])N([H])[C@@]([H])(C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1N1C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H]

Computed Properties

Exact Mass: 452.26800
Monoisotopic Mass: 452.268
Isotope Atom Count: 0
Hydrogen Bond Donor Count: 2
Hydrogen Bond Acceptor Count: 5
Heavy Atom Count: 33
Rotatable Bond Count: 10
Complexity: 619
Covalently-Bonded Unit Count: 1
Defined Atom Stereocenter Count: 1
Undefined Atom Stereocenter Count : 0
Defined Bond Stereocenter Count: 0
Undefined Bond Stereocenter Count: 0
Topological Polar Surface Area: 78.9
Surface Charge: 0
Tautomer Count: 7
XLogP3: 5.2

Experimental Properties

Color/Form: Powder
Density: 1.1±0.1 g/cm3
Melting Point: 131.0 to 135.0 deg-C
Boiling Point: 672.9°C at 760 mmHg
Flash Point: 360.8±31.5 °C
Refractive Index: 1.567
Solubility: DMSO: 34?mg/mL
PSA: 78.87000
LogP: 5.67580
Merck: 8136
Specific Rotation: D20 +6.97° (c = 0.975 in methanol); D20 +7.45° (c = 1.06 in methanol)
Solubility: Uncertain
Vapor Pressure: 0.0±2.2 mmHg at 25°C

Repaglinide Security Information

Symbol:
Prompt：warning
Signal Word：Warning
Hazard Statement： H302-H361-H362
Warning Statement： P201-P202-P260-P263-P264-P270-P280-P301+P312+P330-P308+P313-P405-P501
Hazardous Material transportation number：NONH for all modes of transport
WGK Germany：2
Safety Instruction： H302+H361+H362
RTECS：000000033825
Toxicity：LD50 orally in rats: >1 g/kg (Grell)
Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month

Repaglinide Customs Data

HS CODE：2933399090
Customs Data：

China Customs Code:
2933399090

Overview:

2933399090. Other compounds with non fused pyridine rings in structure. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%

Declaration elements:

Product Name, component content, use to, Please indicate the appearance of Urotropine, 6- caprolactam please indicate the appearance, Signing date

Summary:

2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Repaglinide Pricemore >>

Related Categories	No.	Product Name	Cas No.	Purity	Specification	Price	update time
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.	R129561-25g	Repaglinide	135062-02-1	≥99%	25g	￥1938.90	2023-09-01
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.	R129561-50mg	Repaglinide	135062-02-1	≥99%	50mg	￥29.90	2023-09-01
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.	R129561-5g	Repaglinide	135062-02-1	≥99%	5g	￥472.90	2023-09-01
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.	R129561-1g	Repaglinide	135062-02-1	≥99%	1g	￥124.90	2023-09-01
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.	R129561-250mg	Repaglinide	135062-02-1	≥99%	250mg	￥59.90	2023-09-01
TI XI AI ( SHANG HAI ) HUA CHENG GONG YE FA ZHAN Co., Ltd.	R0179-1G	Repaglinide	135062-02-1	>98.0%(T)(HPLC)	1g	￥550.00	2024-04-15
S e l l e c k ZHONG GUO	S1426-10mM (1mL in DMSO)	Repaglinide	135062-02-1	99.16%	10mM (1mL in DMSO)	￥732.18	2022-04-26
S e l l e c k ZHONG GUO	S1426-50mg	Repaglinide	135062-02-1	99.87%	50mg	￥809.46	2023-09-16
HE FEI BO MEI SHENG WU KE JI YOU XIAN ZE REN GONG SI	RR9028-100mg	Repaglinide	135062-02-1	≥98%	100mg	￥2650.00 元	2023-09-15
HE FEI BO MEI SHENG WU KE JI YOU XIAN ZE REN GONG SI	RR9028-25mg	Repaglinide	135062-02-1	≥98%	25mg	￥850.00 元	2023-09-15

Repaglinide Production Method

Repaglinide Suppliers

Tiancheng Chemical (Jiangsu) Co., Ltd

Gold Member

Audited Supplier

(CAS:135062-02-1)瑞格列奈

Order Number:LE2753023;LE12979

Stock Status:in Stock

Quantity:25KG,200KG,1000KG

Purity:99%

Pricing Information Last Updated:Friday, 20 June 2025 12:42

Price ($):discuss personally

Email:[email protected]

Suzhou Senfeida Chemical Co., Ltd

Gold Member

Audited Supplier

(CAS:135062-02-1)Repaglinide

Order Number:sfd8991

Stock Status:in Stock

Quantity:200kg

Purity:99.9%

Pricing Information Last Updated:Friday, 19 July 2024 14:35

Price ($):discuss personally

Email:[email protected]

Product Official Link

Repaglinide Spectrogram

MS-MS

13C NMR

1H NMR

300 MHz

DMSO

Repaglinide Related Literature

1. A novel drug–drug coamorphous system without molecular interactions: improve the physicochemical properties of tadalafil and repaglinide

Meiling Su,Yanming Xia,Yajing Shen,Weili Heng,Yuanfeng Wei,Linghe Zhang,Yuan Gao,Jianjun Zhang,Shuai Qian RSC Adv. 2020 10 565
2. Online monitoring of hepatic rat metabolism by coupling a liver biochip and a mass spectrometer

Franck Merlier,Rachid Jellali,Eric Leclerc Analyst 2017 142 3747
3. Interpretation of type 2 diabetes mellitus relevant GC-MS metabolomics fingerprints by using random forests

Jian-Hua Huang,Hua-Lin Xie,Jun Yan,Dong-Sheng Cao,Hong-Mei Lu,Qing-Song Xu,Yi-Zeng Liang Anal. Methods 2013 5 4883
4. Cubosomes as an emerging platform for drug delivery: a review of the state of the art

Mohammed A.S. Abourehab,Mohammad Javed Ansari,Anshul Singh,Ahmed Hassan,Mohamed A. Abdelgawad,Prachi Shrivastav,Bassam M. Abualsoud,Larissa Souza Amaral,Sheersha Pramanik J. Mater. Chem. B 2022 10 2781
5. Exploration and application of a liver-on-a-chip device in combination with modelling and simulation for quantitative drug metabolism studies

Luca Docci,Nicolò Milani,Thomas Ramp,Andrea A. Romeo,Patricio Godoy,Daniela Ortiz Franyuti,Stephan Kr?henbühl,Michael Gertz,Aleksandra Galetin,Neil Parrott,Stephen Fowler Lab Chip 2022 22 1187

Related Categories

Additional information on Repaglinide

Repaglinide (CAS No. 135062-02-1): A Comprehensive Guide to Its Properties, Applications, and Market Trends

Repaglinide, with the CAS number 135062-02-1, is a well-known antidiabetic medication classified as a meglitinide. This compound is primarily used to manage type 2 diabetes mellitus by stimulating insulin secretion from pancreatic beta cells. As the global prevalence of diabetes continues to rise, Repaglinide has gained significant attention for its rapid action and short duration, making it an ideal choice for postprandial glucose control.

The chemical structure of Repaglinide features a carbamoylmethyl benzoic acid derivative, which contributes to its unique pharmacological profile. Unlike sulfonylureas, Repaglinide acts on a distinct receptor site of the pancreatic beta cells, leading to a more glucose-dependent insulin release. This mechanism reduces the risk of prolonged hypoglycemia, a common concern with other antidiabetic drugs.

In recent years, Repaglinide has been the subject of numerous clinical studies exploring its efficacy in combination therapies. Researchers have investigated its potential when used alongside metformin or thiazolidinediones, with promising results for glycemic control. These studies address one of the most frequently searched questions in diabetes management: "What is the best combination therapy for type 2 diabetes?"

The pharmacokinetics of Repaglinide demonstrate rapid absorption, with peak plasma concentrations achieved within 1 hour of oral administration. Its short half-life (approximately 1 hour) makes it particularly suitable for meal-time dosing, allowing patients to adjust their medication based on meal patterns. This flexibility responds to another common patient query: "Can I adjust my diabetes medication based on when I eat?"

From a safety perspective, Repaglinide exhibits a favorable profile for patients with renal impairment, as it undergoes extensive hepatic metabolism with minimal renal excretion. This characteristic makes it a preferred option for diabetic patients with kidney dysfunction, addressing another frequently searched concern in diabetes treatment algorithms.

The global market for Repaglinide has shown steady growth, driven by increasing diabetes prevalence and the demand for personalized diabetes management. Pharmaceutical companies continue to invest in novel formulations of Repaglinide, including fixed-dose combinations and extended-release versions. Market analysts predict sustained interest in this compound as healthcare systems worldwide emphasize precision medicine approaches to chronic disease management.

Recent advancements in drug delivery systems have opened new possibilities for Repaglinide administration. Research into nanoparticle-based formulations aims to enhance bioavailability and reduce dosing frequency, potentially improving patient compliance. These developments align with current trends in pharmaceutical technology and respond to patient searches for "new diabetes treatments 2023" and "advanced drug delivery for diabetes."

From a clinical practice perspective, Repaglinide offers distinct advantages in specific patient populations. Its rapid onset makes it particularly suitable for elderly patients or those with irregular meal patterns. Healthcare professionals frequently search for information on "best antidiabetic for elderly patients" and "diabetes management in shift workers," making these practical applications of Repaglinide particularly relevant to current medical discourse.

The pharmacoeconomics of Repaglinide treatment have also been extensively studied, with analyses demonstrating its cost-effectiveness in certain healthcare systems. As patients and providers increasingly search for "affordable diabetes treatments" and "cost-benefit analysis of antidiabetics," this aspect of Repaglinide therapy remains an important consideration in treatment selection.

Looking to the future, ongoing research continues to explore novel applications of Repaglinide. Some preliminary studies suggest potential benefits beyond glucose control, including possible effects on cardiovascular outcomes in diabetic patients. These emerging areas of investigation respond to growing patient interest in "diabetes medications with heart benefits" and reflect the evolving understanding of diabetes as a multisystem disorder.

In conclusion, Repaglinide (CAS No. 135062-02-1) remains a valuable therapeutic option in the management of type 2 diabetes, with unique pharmacological characteristics that address several current challenges in diabetes care. Its continued relevance in clinical practice and ongoing research developments ensure that Repaglinide will remain an important topic in both medical literature and patient education resources for years to come.

135062-02-1 (Repaglinide) Related Products

Recommended suppliers